Improving Lives – Spotlight on Metabolic Health in Europe
As a new set of MEPs enter the European Parliament, there must be continuation of the hard work done already reshaping the EU’s approach to non-communicable diseases. Ilya Yuffa, Lilly’s Executive Vice President and President Lilly International gives his opinion to the June edition of TheParliament Magazine.
The economic, social and public health costs of noncommunicable diseases (NCDs) are a ticking time-bomb for Europe. Policymakers must take action now to prevent these catastrophic impacts to the European healthcare system and economy. There is no time to waste.
The individual and economic burden of these diseases is rapidly growing, threatening the lives and wellbeing of millions of Europeans, and putting an increased strain on already overstretched European healthcare systems. Obesity, type-2 diabetes, and cardiovascular diseases are closely linked NCDs that share common risk factors, and underlying biological mechanisms that should be targeted with a holistic preventative and management strategy. Unchecked, the growing cost impact of these diseases threatens to overwhelm European economic prosperity.
Read the full article on the website of TheParliament magazine
EU-CAR 2024-141
Related articles
Lilly Receives European Marketing Authorization for tirzepatide (Mounjaro®) in for...
Lilly Receives European Marketing Authorization for tirzepatide (Mounjaro®) in KwikPen® Presentation for Two Indications Brussels, April, 24nd 2024 – Eli Lilly and Company announced that the European Commission (EC) granted marketing authorization (MA) on 19 April 2024 for tirzepatide (Mounjaro®) solution for injection in a multi-dose KwikPen® presentation, for two indications.
Why the Obesity crisis threatens the world's financial stability
The Telegraph post on why the obesity crisis threatens the world's financial stability.
Lilly’s policy position on obesity in Europe
Obesity is a health challenge that has reached epidemic proportions, and it continues to escalate. The EU can play an instrumental role in driving the improvement of obesity care in Member States, with the goal of improving health outcomes and avoiding costly complications. There is a need for immediate action, or else the scale of obesity and its consequences will soon become an unbearable burden on our health systems.